Serotonin and Parkinson's disease: On movement, mood, and madness

Movement Disorders

Volumn 24, Issue 9, 2009, Pages 1255-1266

  Fox, Susan H ^a   Chuang, Rasalinda ^a   Brotchie, Jonathan M ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

5 HT; Anxiety; Constipation; Depression; Dyskinesia; Parkinson's disease; Psychosis; Serotonin

Indexed keywords

3 (2 DIMETHYLAMINOETHYL) 4 CHLORO 5 PROPOXYINDOLE; 4 AMINOBUTYRIC ACID; 5 PROPOXY 3 (1,2,5,6 TETRAHYDRO 4 PYRIDYL)PYRROLO[3,2 B]PYRIDINE; APOMORPHINE; BROMOCRIPTINE; BUSPIRONE; CABERGOLINE; CLOZAPINE; DOPAMINE; GLUTAMIC ACID; LEVODOPA; LISURIDE; MIRTAZAPINE; MOSAPRIDE CITRATE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PERGOLIDE; PIMAVANSERIN; PLACEBO; PRAMIPEXOLE; QUETIAPINE; RASAGILINE; ROPINIROLE; SARIZOTAN; SEROTONIN; SEROTONIN 1B AGONIST; SEROTONIN 2B RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TEGASEROD; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLINANSERIN;

ABSENCE OF SIDE EFFECTS; AGRANULOCYTOSIS; ANXIETY; BRADYKINESIA; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; DEPRESSION; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG BINDING; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG TARGETING; DYSKINESIA; GASTROINTESTINAL TRACT FUNCTION; GLOBUS PALLIDUS; HUMAN; LOW DRUG DOSE; MENTAL DISEASE; MOOD DISORDER; NEUROTRANSMITTER RELEASE; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PRIORITY JOURNAL; PROTEIN DEPLETION; PSYCHOSIS; REVIEW; RIGIDITY; SEDATION; SEROTONINERGIC SYSTEM; SIDE EFFECT; SUBSTANTIA NIGRA; TREATMENT FAILURE; TREMOR;

AFFECT; ANIMALS; DYSKINESIA, DRUG-INDUCED; HUMANS; MENTAL DISORDERS; MOVEMENT; PARKINSON DISEASE; SEROTONIN; SEROTONIN AGENTS;

EID: 69549126673     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22473     Document Type: Review

References (151)

1. Rapport MM, Green AA, Page IH. Serum vasoconstrictor, serotonin; isolation and characterization. J Biol Chem 1948;176: 1243-1251.
2. Peroutka SJ. 5-HT receptors: past, present and future trends Neuroscience 1995;18:68-69.
3. van der KD, Hattori T. Dorsal raphe cells with collateral projections to the caudate-putamen and substantia nigra: a fluorescent retrograde double labeling study in the rat. Brain Res 1980; 186:1-7.
4. Lavoie B, Parent A. Immunohistochemical study of the serotoninergic innervation of the basal ganglia in the squirrel monkey. J Comp Neurol 1990;299:1-16.
5. Fahn S, Libsch LR, Cutler RW. Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor. J Neurol Sci 1971;14:427-455.
6. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973;20:415-455.
7. Scatton B, Javoy-Agid F, Rouquier L, Dubois B, Agid Y. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res 1983;275: 321-328.
8. Shannak K, Rajput A, Rozdilsky B, Kish S, Gilbert J, Hornykiewicz O. Noradrenaline, dopamine and serotonin levels and metabolism in the human hypothalamus: observations in Parkinson's disease and normal subjects. Brain Res 1994;639:33-41.
9. Kish SJ, Tong J, Hornykiewicz O, et al. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain 2008;131:120-131.
10. Kerenyi L, Ricaurte GA, Schretlen DJ, et al. Positron emission tomography of striatal serotonin transporters in Parkinson disease. Arch Neurol 2003;60:1223-1229.
11. Guttman M, Boileau I, Warsh J, et al. Brain serotonin transporter binding in non-depressed patients with Parkinson's disease. Eur Neurol 2007;14:523-528.
12. Albin RL, Koeppe RA, Bohnen NI, Wernette K, Kilbourn MA, Frey KA. Spared caudal brainstem SERT binding in early Parkinson's disease. J Cereb Blood Flow Metab 2008;28:441-444.
13. D'Amato RJ, Zweig RM, Whitehouse PJ, et al. Aminergic systems in Alzheimer's disease and Parkinson's disease. Ann Neurol 1987;22:229-236.
14. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiology Aging 2003;24:197-211.
15. Halliday GM, Li YW, Blumbergs PC, et al. Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease. Ann Neurol 1990;27:373-385.
16. Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol 1991;50:743-755.
17. Beasley BL, Davenport RW, Chase TN. Fenfluramine hydrochloride treatment of Parkinsonism. Arch Neurol 1977;34:255-256.
18. Jenner P, Sheehy M, Marsden CD. Noradrenaline and 5-hydroxytryptamine modulation of brain dopamine function: implications for the treatment of Parkinson's disease. Br J Clin Pharmacol 1983;15(Suppl 2):277S-289S.
19. Alex KD, Pehek EA. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther 2007;113:296-320.
20. Nicholson SL, Brotchie JM. 5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease - opportunities for novel therapeutics to reduce the problems of levodopa therapy. Eur Neurol 2002;9(Suppl 3):1-6.
21. Brotchie JM. The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease. Ann Neurol 2000; 47(4 Suppl 1):S105-S112.
22. Chase TN. Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology 1998;50(5 Suppl 5): S17-S25.
23. Fox SH, Brotchie JM, Lang AE. Non-dopaminergic treatments in development for Parkinson's disease. Lancet Neurol 2008; 7:927-938.
24. Numan S, Lundgren KH, Wright DE, Herman JP, Seroogy KB. Increased expression of 5HT2 receptor mRNA in rat striatum following 6-OHDA lesions of the adult nigrostriatal pathway. Brain Res Mol Brain Res 1995;29:391-396.
25. Pifl C, Schingnitz G, Hornykiewicz O. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey. Neuroscience 1991;44:591-605.
26. Perez-Otano I, Herrero MT, Oset C, et al. Extensive loss of brain dopamine and serotonin induced by chronic administration of MPTP in the marmoset. Brain Res 1991;567:127-132.
27. Rose S, Nomoto M, Jenner P, Marsden CD. Transient depletion of nucleus accumbens dopamine content may contribute to initial akinesia induced by MPTP in common marmosets. Biochem Pharmacol 1989;38:3677-3681.
28. Richard IH, Maughn A, Kurlan R. Do serotonin reuptake inhibitor antidepressants worsen Parkinson's disease? A retrospective case series. Mov Disord 1999;14:155-157.
29. Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 1996;57:449-454.
30. Arbouw ME, Movig KL, Neef C, Guchelaar HJ, Egberts TC. Influence of initial use of serotonergic antidepressants on antiparkinsonian drug use in levodopa-using patients. Eur J Clin Pharmacol 2007;63:181-187.
31. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 2002;303:791-804.
32. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007;356:29-38.
33. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007;356:39-46.
34. Hofmann C, Penner U, Dorow R, et al. Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis. Clin Neuropharmacol 2006;29:80-86.
35. Fitzgerald LW, Burn TC, Brown BS, et al. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 2000;57:75-81.
36. Bleumink GS, Molen-Eijgenraam M, Strijbos JH, Sanwikarja S, van Puijenbroek EP, Stricker BH. Pergolide-induced pleuropulmonary fibrosis. Clin Neuropharmacol 2002;25:290-293.
37. Kvernmo T, Hartter S, Burger E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther 2006;28:1065-1078.
38. Dodd ML, Klos KJ, Bower JH, Geda YE, Josephs KA, Ahlskog JE. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 2005;62:1377-1381.
39. Grosset KA, Macphee G, Pal G, et al. Problematic gambling on dopamine agonists: Not such a rarity. Mov Disord 2006;21: 2206-2208.
40. Voon V, Hassan K, Zurowski M, et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 2006;67:1254-1257.
41. Weintraub D, Siderowf AD, Potenza MN, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 2006;63:969-973.
42. Avanzi M, Baratti M, Cabrini S, Uber E, Brighetti G, Bonfa F. Prevalence of pathological gambling in patients with Parkinson's disease. Mov Disord 2006;21:2068-2072.
43. Gallagher DA, O'Sullivan SS, Evans AH, Lees AJ, Schrag A. Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series. Mov Disord 2007;22:1757-1763.
44. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002;58:11-17.
45. Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 2005;20:523-539.
46. Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. Eur Neurol 2006;13:1186-1202.
47. Clarke CE, Speller JM, Clarke JA. Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev 2000:CD002259.
48. Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks DJ. Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology 2003;60:601-605.
49. Caretti V, Stoffers D, Winogrodzka A, et al. Loss of thalamic serotonin transporters in early drug-naive Parkinson's disease patients is associated with tremor: an [(123)I]β-CIT SPECT study. J Neural Transm 2008;115:721-729.
50. Gordon PH, Pullman SL, Louis ED, Frucht SJ, Fahn S. Mirtazapine in Parkinsonian tremor. Parkinsonism Relat Disord 2002; 9:125-126.
51. Bonuccelli U, Ceravolo R, Salvetti S, et al. Clozapine in Parkinson's disease tremor. Effects of acute and chronic administration. Neurology 1997;49:1587-1590.
52. Carlson BB, Wisniecki A, Salamone JD. Local injections of the 5-hydroxytryptamine antagonist mianserin into substantia nigra pars reticulata block tremulous jaw movements in rats: studies with a putative model of Parkinsonian tremor. Psychopharmacology (Berl) 2003;165:229-237.
53. Pompeiano M, Palacios JM, Mengod G. Distribution and cellular localization of mRNA coding for 5-HT1A receptor in the rat brain: correlation with receptor binding. J Neurosci 1992;12: 440-453.
54. Frechilla D, Cobreros A, Saldise L, et al. Serotonin 5-HT(1A) receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys. Synapse 2001; 39:288-296.
55. Waeber C, Palacios JM. Serotonin-1 receptor binding sites in the human basal ganglia are decreased in Huntington's chorea but not in Parkinson's disease: a quantitative in vitro autoradiography study. J Neurosci 1989;32:337-347.
56. Chen CP, Alder JT, Bray L, Kingsbury AE, Francis PT, Foster OJ. Post-synaptic 5-HT1A and 5-HT2A receptors are increased in Parkinson's disease neocortex. Ann NY Acad Sci 1998; 861: 288-289.
57. Ng KY, Chase TN, Colburn RW, Kopin IJ. L-Dopa-induced release of cerebral monoamines. Science 1970;170:76-77.
58. Ng KY, Chase TN, Colburn RW, Kopin IJ. Dopamine: stimulation-induced release from central neurons. Science 1971;172: 487-489.
59. Tanaka H, Kannari K, Maeda T, Tomiyama M, Suda T, Matsunaga M. Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 1999;10:631-634.
60. Carta M, Carlsson T, Kirik D, Bjorklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 2007;130:1819-1833.
61. Santiago M, Matarredona ER, Machado A, Cano J. Influence of serotoninergic drugs on in vivo dopamine extracellular output in rat striatum. J Neurosci Res 1998;52:591-598.
62. Kannari K, Yamato H, Shen H, Tomiyama M, Suda T, Matsunaga M. Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-DOPA in the striatum with nigrostriatal denervation. J Neurochem 2001;76:1346-1353.
63. Iravani MM, Tayarani-Binazir K, Chu WB, Jackson MJ, Jenner P. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(1)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\increased motor disability. J Pharmacol Exp Ther 2006;319: 1225-1234.
64. Carlsson T, Carta M, Munoz A, et al. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. Brain 2009;132(Pt 2): 319-335.
65. Antonelli T, Fuxe K, Tomasini MC, et al. Effects of sarizotan on the corticostriatal glutamate pathways. Synapse 2005;58: 193-199.
66. Kita H, Chiken S, Tachibana Y, Nambu A. Serotonin modulates pallidal neuronal activity in the awake monkey. J Neurosci 2007;27:75-83.
67. Tomiyama M, Kimura T, Maeda T, Kannari K, Matsunaga M, Baba M. A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease. Neurosci Res 2005;52:185-194.
68. Dupre KB, Eskow KL, Negron G, Bishop C. The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat. Brain Res 2007;1158:135-143.
69. Eskow KL, Gupta V, Alam S, Park JY, Bishop C. The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy. Pharmacol Biochem Behav 2007;87:306-314.
70. Bishop C, Taylor JL, Kuhn DM, Eskow KL, Park JY, Walker PD. MDMA and fenfluramine reduce L-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation. Eur J Neurosci 2006;23:2669-2676.
71. Iravani MM, Jackson MJ, Kuoppamaki M, Smith LA, Jenner P. 3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates. J Neurosci 2003; 23:9107-9115.
72. Bibbiani F, Oh JD, Chase TN. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 2001;57:1829-1834.
73. Bonifati V, Fabrizio E, Cipriani R, Vanacore N, Meco G. Buspirone in levodopa-induced dyskinesias. Clin Neuropharmacol 1994;17:73-82.
74. Pact V, Giduz T. Mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias. Neurology 1999;53: 1154.
75. Meco G, Fabrizio E, Di Rezze S, Alessandri A, Pratesi L. Mirtazapine in L-dopa-induced dyskinesias. Clin Neuropharmacol 2003;26:179-181.
76. Bara-Jimenez W, Bibbiani F, Morris MJ, et al. Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease. Mov Disord 2005;20:932-936.
77. Olanow CW, Damier P, Goetz CG, et al. Multicenter, openlabel, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin Neuropharmacol 2004;27:58-62.
78. Goetz CG, Damier P, Hicking C, et al. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord 2007;22:179-186.
79. Goetz CG, Laska E, Hicking C, et al. Placebo influences on dyskinesia in Parkinson's disease. Mov Disord 2008;23:700-707.
80. Bartoszyk GD, Van Amsterdam C, Greiner HE, Rautenberg W, Russ H, Seyfried CA. Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. Part 1. Neurochemical profile. J Neural Transm 2004;111:113-126.
81. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999;38:1083-1152.
82. Pazos A, Cortes R, Palacios JM. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors. Brain Res 1985;346:231-249.
83. Brunner D, Buhot MC, Hen R, Hofer M. Anxiety, motor activation, and maternal-infant interactions in 5HT1B knockout mice. Behav Neurosci 1999;113:587-601.
84. Castro ME, Pascual J, Romon T, Berciano J, Figols J, Pazos A. 5-HT1B receptor binding in degenerative movement disorders. Brain Res 1998;790:323-328.
85. Zhang X, Andren PE, Greengard P, Svenningsson P. Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism. Proc Natl Acad Sci USA 2008;105:2163-2168.
86. Knobelman DA, Kung HF, Lucki I. Regulation of extracellular concentrations of 5-hydroxytryptamine (5-HT) in mouse striatum by 5-HT(1A) and 5-HT(1B) receptors. J Pharmacol Exp Ther 2000;292:1111-1117.
87. Stanford IM, Lacey MG. Differential actions of serotonin, mediated by 5-HT1B and 5-HT2C receptors, on GABA-mediated synaptic input to rat substantia nigra pars reticulata neurons in vitro. J Neurosci 1996;16:7566-7573.
88. Rav-Acha M, Bergman H, Yarom Y. Pre- and postsynaptic serotoninergic excitation of globus pallidus neurons. J Neurophysiol 2008;100:1053-1066.
89. Jackson MJ, Al Barghouthy G, Pearce RK, Smith L, Hagan JJ, Jenner P. Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets. Pharmacol Biochem Behav 2004; 79:391-400.
90. Munoz A, Li Q, Gardoni F, et al. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain 2008;131(Part 12):3380-3394.
91. Zhang H, Ma L, Wang F, Chen J, Zhen X. Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease. Neuropharmacology 2007;53:125-133.
92. Di MV, De Blasi A, Di Giulio C, Esposito E. Role of 5-HT(2C) receptors in the control of central dopamine function. Trends Pharmacol Sci 2001;22:229-232.
93. Taylor JL, Bishop C, Ullrich T, Rice KC, Walker PD. Serotonin 2A receptor antagonist treatment reduces dopamine D1 receptor-mediated rotational behavior but not L-DOPA-induced abnormal involuntary movements in the unilateral dopamine-depleted rat. Neuropharmacology 2006;50:761-768.
94. Gomez-Mancilla B, Bedard PJ. Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. Clin Neuropharmacol 1993;16:418-427.
95. Vanover KE, Betz AJ, Weber SM, et al. A 5-HT(2A) receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model. Pharmacol Biochem Behav 2008;90:540-544.
96. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? a new hypothesis. Am J Psychiatry 2001;158:360-369.
97. Grondin R, Doan VD, Gregoire L, Bedard PJ. D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys. Neurology 1999;52:771-776.
98. Visanji NP, Gomez-Ramirez J, Johnston TH, et al. Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord 2006;21:1879-1891.
99. Oh JD, Bibbiani F, Chase TN. Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models. Exp Neurol 2002;177:557-564.
100. Hoyer D, Pazos A, Probst A, Palacios JM. Serotonin receptors in the human brain. II. Characterization and autoradiographic localization of 5-HT1C and 5-HT2 recognition sites. Brain Res 1986;376:97-107.
101. Invernizzi RW, Pierucci M, Calcagno E, et al. Selective activation of 5-HT(2C) receptors stimulates GABA-ergic function in the rat substantia nigra pars reticulata: a combined in vivo electrophysiological and neurochemical study. Neuroscience 2007;144:1523-1535.
102. Rick CE, Stanford IM, Lacey MG. Excitation of rat substantia nigra pars reticulata neurons by 5-hydroxytryptamine in vitro: evidence for a direct action mediated by 5-hydroxytryptamine2C receptors. Neuroscience 1995;69:903-913.
103. Fox SH, Moser B, Brotchie JM. Behavioral effects of 5-HT2C receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp Neurol 1998;151:35-49.
104. Fox SH, Brotchie JM. 5-HT(2C) receptor antagonists enhance the behavioural response to dopamine D(1) receptor agonists in the 6-hydroxydopamine-lesioned rat. Eur J Pharmacol 2000;398: 59-64.
105. Durif F, Debilly B, Galitzky M, et al. Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 2004;62:381-388.
106. Katzenschlager R, Manson AJ, Evans A, Watt H, Lees AJ. Low dose quetiapine for drug induced dyskinesias in Parkinson's disease: a double blind cross over study. J Neurol Neurosurg Psychiatry 2004;75:295-297.
107. Roberts C. ACP-103, a 5-HT2A receptor inverse agonist. Curr Opin Investig Drugs 2006;7:653-660.
108. Schuurman AG, van den AM, Ensinck KT, et al. Increased risk of Parkinson's disease after depression: a retrospective cohort study. Neurology 2002;58:1501-1504.
109. Shiba M, Bower JH, Maraganore DM, et al. Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov Disord 2000;15:669-677.
110. Drevets WC, Thase ME, Moses-Kolko EL, et al. Serotonin-1A receptor imaging in recurrent depression: replication and literature review. Nucl Med Biol 2007;34:865-877.
111. Groenewegen HJ, Uylings HB. The prefrontal cortex and the integration of sensory, limbic and autonomic information. Prog Brain Res 2000;126:3-28.
112. Walter U, Hoeppner J, Prudente-Morrissey L, Horowski S, Herpertz SC, Benecke R. Parkinson's disease-like midbrain sonography abnormalities are frequent in depressive disorders. Brain 2007;130:1799-1807.
113. Braak H, Del Tredici K. Invited article: nervous system pathology in sporadic Parkinson disease. Neurology 2008;70:1916-1925.
114. Halliday GM, Blumbergs PC, Cotton RG, Blessing WW, Geffen LB. Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease. Brain Res 1990;510:104-107.
115. Mayeux R, Stern Y, Williams JB, Cote L, Frantz A, Dyrenfurth I. Clinical and biochemical features of depression in Parkinson's disease. Am J Psychiatry 1986;143:756-759.
116. Kim SE, Choi JY, Choe YS, Choi Y, Lee WY. Serotonin transporters in the midbrain of Parkinson's disease patients: a study with 123I-beta-CIT SPECT. J Nucl Med 2003;44:870-876.
117. Boileau I, Warsh JJ, Guttman M, et al. Elevated serotonin transporter binding in depressed patients with Parkinson's disease: a preliminary PET study with [11C]DASB. Mov Disord 2008; 23:1776-1780.
118. Leentjens AF, Scholtissen B, Vreeling FW, Verhey FR. The serotonergic hypothesis for depression in Parkinson's disease: an experimental approach. Neuropsychopharmacology 2006;31: 1009-1015.
119. Ehrt U, Bronnick K, Leentjens AF, Larsen JP, Aarsland D. Depressive symptom profile in Parkinson's disease: a comparison with depression in elderly patients without Parkinson's disease. Int J Geriatr Psychiatry 2006;21:252-258.
120. Weintraub D, Morales KH, Moberg PJ, et al. Antidepressant studies in Parkinson's disease: a review and meta-analysis. Mov Disord 2005;20:1161-1169.
121. Parks CL, Robinson PS, Sibille E, Shenk T, Toth M. Increased anxiety of mice lacking the serotonin1A receptor. Proc Natl Acad Sci USA 1998;95:10734-10739.
122. Weisstaub NV, Zhou M, Lira A, et al. Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice. Science 2006;313:536-540.
123. Mullins UL, Gianutsos G, Eison AS. Effects of antidepressants on 5-HT7 receptor regulation in the rat hypothalamus. Neuropsychopharmacology 1999;21:352-367.
124. Blier P, Ward NM. Is there a role for 5-HT1A agonists in the treatment of depression? Biol Psychiatry 2003;53:193-203.
125. Chung TH, Deane KH, Ghazi-Noori S, Rickards H, Clarke CE. Systematic review of antidepressant therapies in Parkinson's disease. Parkinsonism Relat Disord 2003;10:59-65.
126. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991; 148:705-713.
127. Bodner RA, Lynch T, Lewis L, Kahn D. Serotonin syndrome. Neurology 1995;45:219-223.
128. Richard IH, Kurlan R, Tanner C, et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group. Neurology 1997;48: 1070-1077.
129. Olanow CW, Rascol O. Early Rasagiline Treatment Slows UPDRS Decline in the ADAGIO Delayed Start Study. Ann Neurol 2008;64(Suppl 12):568.
130. Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov Disord 2007;22:1061-1068.
131. Burnet PW, Eastwood SL, Harrison PJ. 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology 1996;15: 442-455.
132. Joyce JN, Shane A, Lexow N, Winokur A, Casanova MF, Kleinman JE. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology 1993;8:315-336.
133. Naughton M, Mulrooney JB, Leonard BE. A review of the role of serotonin receptors in psychiatric disorders. Hum Psychopharmacol 2000;15:397-415.
134. Breier A. Serotonin, schizophrenia and antipsychotic drug action. Schizophr Res 1995;14:187-202.
135. Cheng AV, Ferrier IN, Morris CM, et al. Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer's and Parkinson's diseases. J Neurol Sci 1991;106:50-55.
136. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. The Parkinson Study Group. N Engl J Med 1999;340:757-763.
137. Miyasaki JM, Shannon K, Voon V, et al. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:996-1002.
138. Fernandez HH, Friedman JH, Jacques C, Rosenfeld M. Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 1999;14:484-487.
139. Juncos JL, Roberts VJ, Evatt ML, et al. Quetiapine improves psychotic symptoms and cognition in Parkinson's disease. Mov Disord 2004;19:29-35.
140. Reddy S, Factor SA, Molho ES, Feustel PJ. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov Disord 2002;17:676-681.
141. Fernandez HH, Trieschmann ME, Burke MA, Jacques C, Friedman JH. Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov Disord 2003;18: 510-514.
142. Ondo WG, Tintner R, Voung KD, Lai D, Ringholz G. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord 2005;20:958-963.
143. Kurlan R, Cummings J, Raman R, Thal L. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology 2007;68:1356-1363.
144. Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration. Mov Disord 2007;22:313-318.
145. Revell S FJMRea. A double-blind, placebo-controlled, dose-escalation trial of pimavanserin in Parkinson's disease and psychosis. Neurology 2008;70(suppl 1):134.
146. Wakabayashi K, Takahashi H, Ohama E, Ikuta F. Parkinson's disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system. Acta Neuropathol 1990;79:581-583.
147. Singaram C, Ashraf W, Gaumnitz EA, et al. Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation. Lancet 1995;346:861-864.
148. Gai WP, Blessing WW, Blumbergs PC. Ubiquitin-positive degenerating neurites in the brainstem in Parkinson's disease. Brain 1995;118:1447-1459.
149. Tazawa S, Masuda N, Koizumi T, Kitazawa M, Nakane T, Miyata H. KDR-5169, a new gastrointestinal prokinetic agent, enhances gastric contractile and emptying activities in dogs and rats. Eur J Pharmacol 2002;434:169-176.
150. Liu Z, Sakakibara R, Odaka T, et al. Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients. Mov Disord 2005;20: 680-686.
151. Sullivan KL, Staffetti JF, Hauser RA, Dunne PB, Zesiewicz TA. Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease. Mov Disord 2006;21:115-116.